12 completed. 12 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 12 |
| Phase 3 | 2 | Completed 2 |
Follow Thrombophilia: new trials by email Literature Review of Thrombophilia trials Research Report on Thrombophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis Placebo Tablet(s), DLBS1033 - Pneumonia, Sepsis | Phase 2 | Completed | Universitas Sebelas Maret | 50 | 2025-08-14 | 2026-10-23 |
| A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) TAK-755 - Thrombotic Thrombocytopenic Purpura (TTP) | Phase 2 | Completed | Takeda | 29 | 2023-07-21 | 2026-06-17 |
| Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC 5-fluorouracil, Docetaxel - Gastric Cancer, Bone Marrow Metastasis | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 24 | 2021-01-15 | 2024-03-25 |
| A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Caplacizumab (ALX-0081), Plasma exchange (PE), Corticosteroid treatment (Methylprednisolone or prednisolone) - Thrombotic Thrombocytopenic Purpura | Phase 2 / Phase 3 | Completed | Sanofi | 21 | 2019-10-21 | 2025-09-22 |
| Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Placebo, SHP655, Standard of Care - Acquired Thrombotic Thrombocytopenic Purpura (aTTP) | Phase 2 | Completed | Shire | 28 | 2019-10-09 | 2022-12-01 |
| Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura rituximab - Thrombotic Thrombocytopenic Purpura | Phase 2 | Completed | Washington University School of Medicine | 19 | 2012-08-01 | 2021-08-17 |
| Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Caplacizumab, Placebo - Acquired Thrombotic Thrombocytopenic Purpura | Phase 2 | Completed | Ablynx, a Sanofi company | 75 | 2011-01-01 | 2023-04-04 |
| Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura rituximab - Thrombotic Thrombocytopenic Purpura | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 12 | 2010-05-01 | 2014-02-27 |
| ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders ARC1779 - Purpura, Thrombotic Thrombocytopenic, Von Willebrand Disease Type-2b | Phase 2 | Completed | Archemix Corp. | 28 | 2008-01-01 | 2009-01-09 |
| Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation ART-123, placebo - Sepsis, Disseminated Intravascular Coagulation | Phase 2 | Completed | Artisan Pharma, Inc. | 750 | 2007-07-01 | 2011-05-18 |
| The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) Rituximab - Thrombotic Thrombocytopenic Purpura (TTP) | Phase 2 | Completed | University College, London | 40 | 2006-03-01 | 2023-05-16 |
| Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency Protein C Concentrate (Human) Vapor Heated - Protein C Deficiency | Phase 2 / Phase 3 | Completed | Baxalta now part of Shire | 18 | 2003-08-22 | 2021-05-05 |
Purpura, Thrombotic Thrombocytopenic (8) · Disseminated Intravascular Coagulation (2) · Sepsis (2) · Blood Coagulation Disorders (1) · Pneumonia (1) · Protein C Deficiency (1) · Stomach Neoplasms (1)
Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Blood Coagulation Disorders (11) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Blood Platelet Disorders (8) · Cytopenia (8) · Hemorrhage (8) · Purpura (8) · Purpura, Thrombocytopenic (8) · Signs and Symptoms (8) · Skin Manifestations (8) · Thrombocytopenia (8) · Thrombotic Microangiopathies (8)
Rituximab (4) · caplacizumab (2) · ADAMTS13 protein, human (1) · ARC 1779 (1) · ART123 (1) · DLBS 1033 (1) · Docetaxel (1) · Fluorouracil (1) · Fumigant 93 (1) · Methylprednisolone (1) · Plasma Exchange (1) · Prednisolone (1) · Protein C (1) · Standard of Care (1) · lumbrokinase (1)
Ablynx, a Sanofi company (1) · Archemix Corp. (1) · Artisan Pharma, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Baxalta now part of Shire (1) · Sanofi (1) · Shire (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Takeda (1) · Universitas Sebelas Maret (1) · University College, London (1) · Washington University School of Medicine (1)
United States (6) · United Kingdom (4) · Austria (3) · France (3) · Italy (3) · Spain (3) · Canada (2) · Germany (2) · Australia (1) · Belgium (1) · Bulgaria (1) · China (1) · Greece (1) · Indonesia (1) · Israel (1)
Elaine M Majerus, MD, PhD (1) · Eldaa Putik Bunga Melati, MD (1) · Jian Xiao, MD (1) · Marie A Scully, MBBS, BSc, MRCPath (1)
PMID 12353309, PMID 15389904, PMID 20058208, PMID 21636861, PMID 22475545, PMID 23279219, PMID 26863353, PMID 27643485, PMID 30957581, PMID 33881463, PMID 36346044, PMID 36427162, PMID 39095866
2018 (1), 2023 (1), U54HL112303 (1)